PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1824
https://www.valueinhealthjournal.com/article/S1098-3015(19)34202-0/fulltext
Title :
PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34202-0&doi=10.1016/j.jval.2019.09.1824
First page :
Section Title :
Open access? :
No
Section Order :
11584